This is a routine administrative filing. Monitor for future prospectus supplements that could specify actual offering size, pricing, and use of proceeds under the ATM or new debt facility. The company's cash runway from the upcoming 10-Q (if available) should guide urgency of any capital raise.
Price Chart
Executive Summary
Plus Therapeutics filed Pre-Effective Amendment No. 1 to its Form S-3 shelf registration (File No. 333-296411) as an exhibits-only filing to add a form of indenture for potential future debt securities. The original S-3, filed June 2, 2026, includes an Equity Distribution Agreement with Canaccord Genuity LLC for an at-the-market (ATM) common stock facility. This amendment is procedural and does not introduce new offering terms, size, or pricing.
Key Facts
- Pre-Effective Amendment No. 1 to S-3 shelf registration filed June 5, 2026 (File No. 333-296411).
- Exhibits-only filing adding a form of indenture for debt securities; no new offering terms or size disclosed.
- Original S-3 (June 2, 2026) includes an Equity Distribution Agreement with Canaccord Genuity LLC for ATM common stock sales.
- Company is a smaller reporting company and emerging growth company with ~$40M market cap.
- Cross-filing: 10-Q filed May 15, 2026; truncated financial data provides incomplete picture of cash position.
Financial Impact
No offering size or pricing disclosed in this amendment; potential dilutive impact from existing ATM facility is already reflected in the market.
Risk Factors
- Potential equity dilution from ATM facility once drawdowns occur.
- Potential additional leverage from future debt offerings under the new indenture.
- Uncertain financial position due to truncated 10-Q data; may require capital sooner than expected.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3/A Filing (Primary) | 0001193125-26-258388 |
| Document: d138711ds3a.htm | 0001193125-26-258388 |
| Document: 0001193125-26-258388-index-headers.html | 0001193125-26-258388 |
| Document: 0001193125-26-258388-index.html | 0001193125-26-258388 |
| Document: 0001193125-26-258388.txt | 0001193125-26-258388 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 21, 2026 14w ago | Press Release | $3.92 | awaiting T+20 | — | — |
Jun 30, 2026 17w ago | Press Release | $4.37 $3.73 | ▼ −14.65% | ▼ −13.62% | — |
Jun 8, 2026 20w ago | EFFECT | $5.53 $4.05 | ▲ +26.76% | ▲ +28.39% | — |
Jun 5, 2026 20w ago | S-3/A | $5.41 $4.05 | ▼ −25.14% | ▼ −27.00% | — |
May 19, 2026 23w ago | Press Release | $5.83 $4.31 | ▼ −26.07% | ▼ −27.06% | — |
May 15, 2026 23w ago | Press Release | $5.84 $4.57 | ▲ +21.75% | ▲ +23.33% | — |
May 8, 2026 24w ago | Press Release | $6.12 $5.41 | ▼ −11.60% | ▼ −11.62% | — |
Apr 28, 2026 26w ago | Press Release | $5.95 $6.60 | ▲ +10.92% | ▲ +5.46% | — |
Apr 21, 2026 27w ago | 8-K | $7.14 $5.84 | ▼ −18.21% | ▼ −23.12% | — |
Apr 9, 2026 28w ago | 8-K | $3.92 $6.00 | ▲ +53.06% | ▲ +45.49% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers